Taxing the UK Drugs Market
Matthew
J Atha BSc MSc LLB
Independent Drug Monitoring Unit
Click here to download as pdf
IDMU has conducted surveys
of drug consumption in the UK over the past 10 years,
involving a total of nearly 15000 UK drug users recruited
at pop festivals and other outdoor events using anonymous
self-completed questionnaires, collecting data on frequency
of use of a range of different drugs, monthly spending
on these drugs, among other data including whether the
respondent had been "busted" for cannabis
or other drugs.
Estimating Prevalence
Cannabis
An estimate of the number
of regular cannabis users in the UK can be arrived with
reference to the proportion of the sample who have been
arrested for cannabis offences, their average duration
of cannabis use (average age minus age first used cannabis)
and the total number of cannabis convictions in the
UK over the periods in question (historic data from
Home Office statistical bulletins). Between 1945 and
2002, there were around 1.23 million cannabis convictions
in the UK, the vast majority in the past 10 years.
Year
|
% Busted Cannabis offences
|
Avg Duration (yrs)
|
Busts /use year
|
Convictions over avg duration
|
% Regular Users in survey
|
Estimated Number of Regular Users
|
1994
|
21.2%
|
9.18
|
2.31%
|
270250
|
75.5%
|
961,073
|
1995
|
25.3%
|
8.69
|
2.91%
|
295695
|
85.9%
|
1,005,198
|
1997
|
21.0%
|
9.45
|
2.23%
|
362966
|
70.1%
|
1,209,383
|
1998
|
23.2%
|
12.78
|
1.82%
|
605532
|
67.3%
|
1,753,261
|
1999
|
21.4%
|
11.48
|
1.86%
|
655547
|
71.0%
|
2,175,048
|
2000
|
19.6%
|
11.42
|
1.71%
|
718519
|
68.5%
|
2,516,565
|
2001
|
18.2%
|
11.54
|
1.58%
|
768654
|
73.6%
|
3,106,950
|
2002
|
15.1%
|
12.80
|
1.18%
|
850228
|
58.2%
|
3,273,777
|
2003
|
17.0%
|
11.39
|
1.50%
|
839902
|
68.0%
|
3,350,801
|
1994-2003
|
18.2%
|
10.89
|
1.67%
|
818891
|
67.9%
|
2,150,228
|
Prevalence of other drugs
Taking the survey data as
a whole, these would represent approximately 3.1 million
drug users in the UK (not all of whom use cannabis).
By applying the proportions of survey respondents who
reported lifetime and/or regular use of other drugs,
an estimate of prevalence can be calculated.
Drug
|
Total Ever
|
%
|
Regular
|
%
|
Lifetime
|
Regular
|
Occ/Exp
|
Amphetamine
|
6174
|
42.4%
|
957
|
6.6%
|
1333385
|
206681
|
1126704
|
Cocaine
|
5154
|
35.4%
|
852
|
5.9%
|
1113098
|
184005
|
929093
|
Crack
|
1026
|
7.1%
|
107
|
0.7%
|
221583
|
23109
|
198474
|
Heroin
|
1257
|
8.6%
|
133
|
0.9%
|
271471
|
28724
|
242748
|
Ecstasy
|
5592
|
38.4%
|
1832
|
12.6%
|
1207692
|
395653
|
812039
|
LSD
|
5883
|
40.4%
|
685
|
4.7%
|
1270538
|
147938
|
1122600
|
Base
|
14552
|
|
Total Users @ 2003
|
3142763
|
|
|
It is accepted that estimates
of heroin and crack cocaine are likely to be low, due
to the methods of data collection at pop festivals and
other outdoor venues frequented by recreational drug
users, where problem drug users tend to be unwelcome,
and unable to afford the entry prices. For historical
reasons, our figures are likely to overestimate the
current value of the LSD and Amphetamine which have
declined in popularity in favour of ecstasy and cocaine.
Bramley-Harker [2001][1]
of NERA estimated drug prevalence and spending for the
Home Office, and arrived at the following figures for
prevalence of regular users for the following drugs,
from prevalence of drug positive urine specimens from
arrestees[2].
The methodology was effective at detecting users of
stimulants and opiates, who tend to be more likely to
come to police attention than users of cannabis and
hallucinogens.
Drug
|
Regular Users
|
Cannabis
|
595797
|
Amphetamines
|
116725
|
Cocaine
|
237180
|
Crack
|
102606
|
Heroin
|
156166
|
Ecstasy
|
76354
|
The British Crime Survey
is a household survey which asks interviewees whether
they have ever used a range of drugs and if so whether
they have used these in the past year or past month.
Bennett found that approximately 25% of users with positive
tests failed to report use of that drug when interviewed,
suggesting their estimates of prevalence should be increased
by approximately 33%. The BCS figures for 2000, the
most recent year with full details published, were as
follows
Drug
|
Lifetime
|
Past Year
|
Past Month
|
Cannabis
|
4839231
|
2330000
|
1510000
|
Amphetamine
|
2258308
|
562414
|
188750
|
Cocaine
|
1075385
|
572000
|
253000
|
Crack
|
215077
|
107000
|
53000
|
Heroin
|
215077
|
95000
|
60000
|
Ecstasy
|
1182923
|
401724
|
215714
|
LSD
|
1182923
|
160690
|
52069
|
Maximum and Minimum Figures
for regular users. Regular users typically account for
in excess of 80% of the value of the market for most
commodities, and drugs are no exception.
Drug
|
IDMU
|
NERA Regular
|
BCS Month
|
Min Estimate
|
Max Estimate
|
Cannabis
|
3,350,801
|
595797
|
1510000
|
595797
|
3,350,801
|
Amphetamine
|
206681
|
116725
|
188750
|
116725
|
206681
|
Cocaine
|
184005
|
237180
|
253000
|
184005
|
253000
|
Crack
|
23109
|
102606
|
53000
|
23109
|
102606
|
Heroin
|
28724
|
156166
|
60000
|
28724
|
156166
|
Ecstasy
|
395653
|
76354
|
215714
|
76354
|
395653
|
LSD
|
147938
|
-
|
52069
|
52069
|
147938
|
Monthly Spending on Drugs
Respondents to IDMU surveys
are asked to state how much they spend on a range of
drugs during an "average month", and how often
they use a particular drug. Regular use is categorised
as use monthly or more often.
Drug
|
Regular
|
Occasional
|
Cannabis
|
£ 86.67
|
£ 36.45
|
Amphetamines
|
£ 102.24
|
£ 26.31
|
Cocaine
|
£ 168.74
|
£ 33.90
|
Crack
|
£ 444.59
|
£ 27.59
|
Heroin
|
£ 447.40
|
£ 24.65
|
Ecstasy
|
£ 39.62
|
£ 19.23
|
LSD
|
£ 18.89
|
£ 6.99
|
Value of the UK
Drugs Market
Spending by regular users
Regular users of any particular
drug account for the bulk of spending on that drug.
Applying the IDMU spending data to the minimum and maximum
prevalence estimates for regular users, annual spending
by regular users can be calculated at between £1.46
billion and £5.86 billion per year.
Drug
|
Minimum Estimate
|
Maximum Estimate
|
Monthly Spending
|
Minimum
Value
|
Maximum Value
|
Cannabis
|
595797
|
3,350,801
|
£ 86.67
|
£ 619,652,712
|
£ 3,484,967,072
|
Amphetamine
|
116725
|
206681
|
£ 102.24
|
£ 143,207,568
|
£ 253,572,785
|
Cocaine
|
184005
|
253000
|
£ 168.74
|
£ 372,588,044
|
£ 512,294,640
|
Crack
|
23109
|
102606
|
£ 444.59
|
£ 123,288,364
|
£ 547,411,218
|
Heroin
|
28724
|
156166
|
£ 447.40
|
£ 154,213,411
|
£ 838,424,021
|
Ecstasy
|
76354
|
395653
|
£ 39.62
|
£ 36,301,746
|
£ 188,109,262
|
LSD
|
52069
|
147938
|
£ 18.89
|
£ 11,803,001
|
£ 33,534,586
|
Total Spending by Regular Users
|
£ 1,461,054,846
|
£ 5,858,313,585
|
Spending by Occasional
Users
Total spending by occasional
drug users would be worth roughly £687 million per year.
Spending
on Drugs by Occasional Users
|
Drug
|
Occasional Users
|
Monthly Spending
|
% of min
|
% of max
|
Total Occasional Users Value
|
Cannabis
|
820,000
|
£ 36.45
|
37%
|
9%
|
£ 358,668,000
|
Amphetamine
|
373664
|
£ 26.31
|
45%
|
32%
|
£ 117,973,133
|
Cocaine
|
319000
|
£ 33.90
|
26%
|
20%
|
£ 129,769,200
|
Crack
|
54000
|
£ 27.59
|
13%
|
3%
|
£ 17,878,320
|
Heroin
|
35000
|
£ 24.65
|
6%
|
1%
|
£ 10,353,000
|
Ecstasy
|
186010
|
£ 19.23
|
54%
|
19%
|
£ 42,923,633
|
LSD
|
108621
|
£ 6.99
|
44%
|
21%
|
£ 9,111,103
|
Total Spending by Occasional Users
|
32%
|
10%
|
£ 686,676,390
|
Overall size of UK Drugs
market:
The total size of the UK
drugs market would thus be estimated at between £2.15
Billion and £6.54 Billion per annum.
Total
Value of UK Drugs Market
|
Drug
|
Minimum Value
|
Maximum Value
|
Share of min
|
Share of max
|
Cannabis
|
£ 978,320,712
|
£ 3,843,635,072
|
46%
|
59%
|
Amphetamine
|
£ 261,180,701
|
£ 371,545,918
|
12%
|
6%
|
Cocaine
|
£ 502,357,244
|
£ 642,063,840
|
23%
|
10%
|
Crack
|
£ 141,166,684
|
£ 565,289,538
|
7%
|
9%
|
Heroin
|
£ 164,566,411
|
£ 848,777,021
|
8%
|
13%
|
Ecstasy
|
£ 79,225,379
|
£ 231,032,896
|
4%
|
4%
|
LSD
|
£ 20,914,104
|
£ 42,645,689
|
1%
|
1%
|
Total
|
£ 2,147,731,236
|
£ 6,544,989,974
|
100%
|
100%
|
Potential for
Excise Duties
2003 UK Drug Prices &
Profit Margins:
Current prices of drugs,
from 2003 survey. Production costs are based on the
following:
Cocaine/Crack
- $2000 per kilo (Columbia) at 70%, ounce/gram @ 40%
Cannabis Resin
- £150 per kilo (Morocco), UK Kilo and 1/8oz prices
Cannabis Skunk
" estimated £170 per kilo in electricity, nutrients
and equipment, UK Kilo and 1/8oz prices
Amphetamine/Heroin
" Pharmaceutical prices at 100%, retail at typical
street purity, wholesale amphet at "base"
prices @ 40%, street @ 14%, heroin at 50% purity
LSD/Ecstasy
" guesstimates for production, UK 100 tab and 1
tab prices
2003
UK Drug Prices per gram equivalent
|
Drug
|
Production Cost
|
Distributor Price
|
Max Retail Price
|
Cannabis Resin
|
£ 0.15
|
£ 0.90
|
£ 2.85
|
Cannabis Skunk
|
£ 1.70
|
£ 2.85
|
£ 5.75
|
Amphetamine*
|
£ 6.86
|
£ 12.67
|
£ 60.64
|
Cocaine*
|
£ 1.20
|
£ 35.10
|
£ 117.65
|
Crack*
|
£ 1.50
|
£ 40.17
|
£ 139.63
|
Heroin*
|
£ 12.30
|
£ 57.14
|
£ 207.20
|
LSDâ
|
£ 0.20
|
£ 1.51
|
£ 3.91
|
Ecstasyâ
|
£ 0.20
|
£ 1.58
|
£ 4.02
|
* Per pure gram - â Per tab/dose
|
UK Drug Price Trends
Prices of cannabis resin,
ecstasy and heroin have fallen sharply in recent years
(all by 50% or more), although skunk, amphetamine and
cocaine prices have remained stable, and LSD prices
have increased over the past 10 years.
UK
Drug Price Trends 1995-2003
|
Drug
|
1995
|
1997
|
1998
|
1999
|
2000
|
2001
|
2002
|
2003
|
Resin 8th
|
£ 14.39
|
£ 14.06
|
£ 13.64
|
£ 12.88
|
£ 12.01
|
£ 11.29
|
£ 10.74
|
£ 9.96
|
Skunk 8th
|
£ 20.21
|
£ 20.63
|
£ 20.82
|
£ 20.98
|
£ 20.70
|
£ 19.94
|
£ 19.95
|
£ 20.14
|
Amphet gram
|
£ 8.28
|
£ 8.07
|
£ 8.04
|
£ 8.74
|
£ 8.43
|
£ 8.71
|
£ 8.85
|
£ 8.49
|
Cocaine gram
|
£ 56.66
|
£ 50.51
|
£ 51.92
|
£ 50.55
|
£ 49.38
|
£ 46.20
|
£ 47.95
|
£ 47.06
|
Crack rock
|
£ 21.50
|
£ 21.64
|
£ 19.38
|
£ 23.65
|
£ 20.48
|
£ 18.91
|
£ 22.23
|
£ 22.34
|
Heroin gram
|
£ 83.33
|
£ 69.69
|
£ 71.25
|
£ 56.40
|
£ 60.00
|
£ 54.00
|
£ 48.54
|
£ 35.83
|
LSD Tab
|
£ 2.99
|
£ 3.25
|
£ 3.28
|
£ 3.26
|
£ 3.53
|
£ 3.73
|
£ 3.68
|
£ 3.91
|
Ecstasy tab
|
£ 11.65
|
£ 9.84
|
£ 9.46
|
£ 8.38
|
£ 6.99
|
£ 6.24
|
£ 5.47
|
£ 4.02
|
Market Shares of Illicit
Drugs
Cannabis accounts for the
vast majority of spending on drugs in the UK, and clear
trends are apparent, notably an increase in the use
of cocaine and crack at the expense of amphetamine,
and an increase in heroin usage. Use of LSD is in long-term
decline, and ecstasy use may have peaked, with a fall
in market share over the past two years,
The key to maximising excise
revenues is to keep the user price low enough to undercut
the illicit market, learning the lessons of cross-channel
alcohol and tobacco smuggling. Furthermore, if the worldwide
market was liberalised, the "crime tariff"
would be reduced across the board, in the illicit as
well as the newly-legitimate and licensed market.
The fall in prices of cannabis
resin, heroin and ecstasy has highlighted the potential
for the illicit market to cut prices, and the criminal
organisations currently involved in smuggling drugs
have the infrastructure in place to continue importing
from producer countries. The fall in the prices of these
drugs shows no signs of bottoming out at the present
time, and it is conceivable that cannabis resin could
become as cheap as £5 per 1/8oz (3.5g), ecstasy at £2
per tablet and heroin at £20 per gram, within the next
5 years if current trends continue.
One solution is for the
legitimate market, whether state/UN controlled, or licensed
private companies, to purchase the drugs at source from
the producers, paying a better price than the smuggling
cartels, and depriving the cartels of their raw material.
For the heroin and cocaine markets, this would be cheaper
than the current worldwide expenditure on interdiction
and within the criminal justice systems treatment of
offenders.
Excise Duty Levels &
Estimated Revenues
Realistic levels of excise
duty would not therefore exceed the following levels,
representing approximately 50% of the anticipated retail
price. Duty levels could be related to purity or potency
of the drug, as is the case with alcohol.
Cannabis Resin (<10%
THC) - £1 per gram
Cannabis Skunk (>10%
THC) - £2 per gram
Amphetamine (15% purity)
- £3 per gram
Cocaine (40% purity)
- £15 per gram
Crack (80% purity) -
£30 per gram
Heroin (50% purity) -
£15 per gram
LSD " £1 per tab
(80 µg)
Ecstasy - £1 per tab
(80mg)
At
the above levels of duty, and the minimum/maximum market
estimates above, the potential duty revenues which could
be raised would fall between £878 Million and £2.86
billion. Also, assuming duty represents 50% of the retail
price, the VAT revenues from retail sales would fall
between £307 million and £1 billion, the total take
for the exchequer falling between £1.185 billion and
£3.864 billion per annum.
Potential
Excise Duty Revenues
|
Drug
|
Unit price 2003
|
Min Units
|
Max Units
|
Duty per unit
|
Min Duty
|
Max Duty
|
Resin
|
£ 2.85
|
154471691
|
606889748
|
£ 1.00
|
£ 154,471,691
|
£ 606,889,748
|
Skunk
|
£ 5.75
|
93578503
|
367652050
|
£ 2.00
|
£ 187,157,006
|
£ 735,304,101
|
Amphetamine
|
£ 8.49
|
30763333
|
43762770
|
£ 3.00
|
£ 92,290,000
|
£ 131,288,310
|
Cocaine
|
£ 47.06
|
10674825
|
13643516
|
£ 15.00
|
£ 160,122,368
|
£ 204,652,733
|
Crack
|
£ 22.34
|
6319010
|
25303918
|
£ 30.00
|
£ 189,570,301
|
£ 759,117,553
|
Heroin
|
£ 35.83
|
4592978
|
23689004
|
£ 15.00
|
£ 68,894,674
|
£ 355,335,063
|
LSD
|
£ 3.91
|
20262245
|
59087697
|
£ 1.00
|
£ 20,262,245
|
£ 59,087,697
|
Ecstasy
|
£ 4.02
|
5202513
|
10608380
|
£ 1.00
|
£ 5,202,513
|
£ 10,608,380
|
Total
|
325865099
|
1150637084
|
|
£ 877,970,799
|
£ 2,862,283,586
|
|
|
|
|
VAT 17..5%
|
£ 307,289,780
|
£ 1,001,799,255
|
|
|
|
|
Total
|
£ 1,185,260,579
|
£ 3,864,082,841
|
Domestic
Cannabis Cultivation
Domestically produced cannabis
currently accounts for over 50% of the UK Market. Systems
range from small cupboards to industrial units, with
the typical system involving a spare room partitioned
into separate areas for growth and flowering. It is
reasonable to assume that such levels of production
would continue or even increase following a change in
the law.
Growers could be licensed
to cultivate cannabis for personal use or social supply,
with the licence permitting cultivation (flowering)
of cannabis plants up to a certain surface area and/or
wattage of lighting, based on a reasonable estimate
as to the production capacity of a typical system of
such size.
Enforcement of licensing
conditions for domestic cultivation would be one of
the duties of Offdrug, with growers subject to random
inspections to ensure conditions are not breached. Any
unlicensed growers would face the full force of the
law.
Expenditure Savings
Based on separate estimates
from the late 1990s[3][4], the current cost of enforcing
drug prohibition is likely to fall between £1.5 billion
and £2 billion per annum. The cost of processing users
and traffickers through the criminal justice system
would be dramatically reduced in a licensing regime,
although some costs would remain for prosecution of
unlicensed suppliers or growers.
Knock-on benefits
Our 1994-1997 surveys[5]
found that users who had a drugs record earned, on average,
approximately £1000 per year less than those users with
a clean criminal record. The benefits of financial activity
would be most keenly felt among those users most dependent
on state benefits but who, given a clean supply of drugs,
could be expected to develop marketable skills. This
would result in reduced benefit expenditure and income
tax revenues, possibly to the extent of a further £1
billion per year.
New Costs
There would be additional
cost implications in the following areas:
Excise duty collection
and testing of samples for purity to determine duty
payable.
Regulation and processing
of licence applications (Offdrug)
Policing of compliance
with licensing regulations
Law enforcement costs in
respect of smuggling and unlicensed sales
Health education, prevention
costs & treatment costs (some health costs may be
offset via wider medicinal uses of cannabis)
Total costs of Offdrug would
be anticipated in the region of £250-£500 million per
annum
Models of Distribution
The preferred model of distribution
would aim to satisfy existing demand without attracting
new customers, via regulation. Different drugs would
require different levels of regulatory control.
Cannabis Cafes
These are successful in the Netherlands, allowing sales
to the public with a maximum which could be purchased
at any one time
Members Clubs
These could operate on a model similar to Working Men"s
clubs, providing drugs to members, with reciprocal arrangements
for affiliated clubs in other conurbations
Licensing Users
A user of current class A drugs could be licensed to
purchase a certain quantity of drugs (e.g. from a chemist),
having to produce a "smart card" to do so.
General sales (Off Licence)
Cannabis products could be sold commercially via off
licences and tobacconists. This model should not be
considered for other drugs, for which some restraint
on consumption is desirable.
Prescription
Similar to licensing users, although the control of
supply is in the hands of the doctor rather than Offdrug"
Changes in Prevalence
One anticipated consequence
of a change in the law would be an increase in the prevalence
of drug use. IDMU surveys have addressed this question
by asking respondents who had not yet used a drug whether
or not they would consider doing so in the future.
Market
Saturation
|
Drug
|
Might Use
|
Ever Used
|
Total Non-Users
|
Potential Increase
|
Cannabis
|
31
|
9554
|
4998
|
0.32%
|
Amphetamine
|
171
|
6174
|
8378
|
2.77%
|
Cocaine
|
306
|
5154
|
9398
|
5.94%
|
Crack
|
223
|
1026
|
13256
|
21.73%
|
Heroin
|
193
|
1257
|
13295
|
15.35%
|
LSD
|
381
|
5883
|
8669
|
6.48%
|
Ecstasy
|
304
|
5592
|
8960
|
5.44%
|
The figures for cannabis
are skewed by the targeting of cannabis users within
the survey methodology. The figures for crack and heroin
do give cause for concern, although these partially
reflect the relatively small numbers of respondents
who had tried these drugs, the vast majority of whom
were experimental or occasional users.
It is likely that prevalence
of cannabis use would increase most dramatically among
the older generation, in particular pensioners using
the drug medicinally, as the generation most likely
to be deterred by illegality, rather than regarding
it as a challenge as do many younger users. It is possible
that if cannabis is no longer forbidden it may lose
much of its sweetness among the younger generation,
and fall out of fashion as a symbol of rebellion.
Conclusion
Licensing and regulating the drugs trade would require
international agreement to work effectively, with purchase
of drugs at source from producers in developing countries.
The UK could go it alone, and licence domestic cultivation
and supply, although there will always be a demand for
higher quality cannabis resins (e.g. Moroccan Pollen,
Charas, Nepalese, Minali etc), although this could partially
be supplied by (potentially very high potency) resins
produced from domestic plants.
The financial effects of
legalisation and regulation of the drugs trade would
have benefits " in excise duty, VAT, general economic
growth and expenditure savings, with modest additional
expenditure required to establish a regulatory authority
and give the regulator effective "teeth" to
tackle abuses of the system.
Revenue
Implications
|
Item
|
Minimum
|
Maximum
|
Excise
Duty
|
£ 877,970,799
|
£ 2,862,283,586
|
VAT
|
£ 307,289,780
|
£ 1,001,799,255
|
Income
Tax
|
£ 1,000,000,000
|
£ 1,000,000,000
|
Savings
|
£ 1,500,000,000
|
£ 2,000,000,000
|
Total
|
£ 3,685,260,579
|
£ 6,864,082,841
|
New
costs
|
-£ 250,000,000
|
-£ 500,000,000
|
Net
Benefit
|
£
3,435,260,579
|
£
6,364,082,841
|
Regulation and licensing
of the drugs trade could reasonably be expected to result
in a net gain to the exchequer of between £3.4 billion
and £6.4 billion per annum.
Matthew J Atha
BSc MSc LL.B
Independent Drug
Monitoring Unit
5 October 2004